148 related articles for article (PubMed ID: 15604942)
1. Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake.
Marshall C; Eremin J; El-Sheemy M; Eremin O; Griffiths PA
Nucl Med Commun; 2005 Jan; 26(1):9-15. PubMed ID: 15604942
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of (99m)Tc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer.
Alonso O; Delgado L; Núñez M; Vargas C; Lopera J; Andruskevicius P; Sabini G; Gaudiano J; Musé IM; Roca R
Nucl Med Commun; 2002 Aug; 23(8):765-71. PubMed ID: 12124482
[TBL] [Abstract][Full Text] [Related]
3. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O
Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
5. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
Dunnwald LK; Gralow JR; Ellis GK; Livingston RB; Linden HM; Lawton TJ; Barlow WE; Schubert EK; Mankoff DA
Cancer; 2005 Feb; 103(4):680-8. PubMed ID: 15637688
[TBL] [Abstract][Full Text] [Related]
6. Response of malignant breast tumours to neoadjuvant chemotherapy evaluated with Tc-99m MIBI.
Listewnik MH; Birkenfeld B; Foszczyńska-Kłoda M; Listewnik MJ; Piwowarska-Bilska H; Zorga P
Ann Acad Med Stetin; 2011; 57(1):73-8. PubMed ID: 22593995
[TBL] [Abstract][Full Text] [Related]
7. Different methods for the detection of small changes in uptake between single-photon emission computed tomography (SPECT) examinations: 99mTc-sestamibi in chemotherapy for breast tumours.
Jacobsson H; Wilczek B; Bergh J; von Schoultz E; Eriksson E; Larsson SA
Nucl Med Commun; 2006 Apr; 27(4):347-52. PubMed ID: 16531920
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Drucker MJ; Livingston RB
Cancer; 1999 Jun; 85(11):2410-23. PubMed ID: 10357412
[TBL] [Abstract][Full Text] [Related]
9. Dual phase qualitative and quantitative 99mTc-MIBI scintimammography for predicting response to neoadjuvant chemotherapy in breast cancer.
Zaman MU; Nasir Z; Raza T; Hashmi H; Hashmi A; Fatima N
J Coll Physicians Surg Pak; 2009 Mar; 19(3):173-8. PubMed ID: 19268018
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
[TBL] [Abstract][Full Text] [Related]
11. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
12. Detection of bilateral, multifocal breast cancer and assessment of tumour response to neoadjuvant chemotherapy by Tc-99m sestamibi imaging - a case report.
Grosso M; Imran MB; Volterrani D; Roncella M; Abufalgha K; Grassetto G; Al-Nahhas A; Rubello D; Mariani G
Nucl Med Rev Cent East Eur; 2008; 11(2):70-2. PubMed ID: 19585458
[TBL] [Abstract][Full Text] [Related]
13. [Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
Liu ZZ; Lu ZD; Zhang HW; Yang H; Liu H; Li LF; Li WL; Cui SD
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):544-6. PubMed ID: 22093636
[TBL] [Abstract][Full Text] [Related]
14. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients.
Takamura Y; Miyoshi Y; Taguchi T; Noguchi S
Cancer; 2001 Jul; 92(2):232-9. PubMed ID: 11466674
[TBL] [Abstract][Full Text] [Related]
15. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis.
Guo C; Zhang C; Liu J; Tong L; Huang G
Nucl Med Commun; 2016 Jul; 37(7):675-88. PubMed ID: 26974314
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the response to docetaxel-based chemotherapy for locoregionally advanced nasopharyngeal carcinoma: the role of double-phase (99m)Tc-MIBI SPECT/CT.
Du C; Ying H; Zhou J; Jiang J; Liu C; Chen J; Wang X; Hu C
Med Oncol; 2014 Feb; 31(2):833. PubMed ID: 24402323
[TBL] [Abstract][Full Text] [Related]
17. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
[TBL] [Abstract][Full Text] [Related]
19. Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer.
Kim R; Osaki A; Hirai T; Toge T
Breast Cancer; 2002; 9(3):240-7. PubMed ID: 12185336
[TBL] [Abstract][Full Text] [Related]
20. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer.
Cwikla JB; Buscombe JR; Barlow RV; Kelleher SM; Parbhoo SP; Crow J; Deery A; Jones AL; Hilson AJ
Eur J Nucl Med; 1997 Sep; 24(9):1175-8. PubMed ID: 9283114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
